InnoCan Pharma (INNO) Q1 2025 earnings summary

Executive summary

• Achieved a positive swing in operating profitability for the first half of 2025, despite challenging market conditions.

• Focused on strategic execution in multiple target markets, emphasizing opioid-free chronic pain relief and consumer wellness growth opportunities.

• Progressing toward a U.S. public offering and Nasdaq listing, aiming to expand capital access and market presence.

Financial highlights

• Revenues decreased 4% year-over-year to $14.8M for H1 2025, attributed to global trade tariff volatility.

• Gross profit declined 4.9% year-over-year to $13.3M in H1 2025.

• Operating profit improved to $0.885M in H1 2025, up 130% from an operating loss of $0.68M in H1 2024.

Outlook and guidance

• Anticipates significant growth opportunities in the Consumer Wellness segment.

• Advancing LPT-CBD platform for chronic pain, with late pre-clinical development showing sustained pharmacokinetics and favorable tolerability.

• Exploring strategic expansion of distribution channels and continued product innovation.